Myasthenia Gravis Drugs Market 2018 Global Share, Trend, Segmentation and Forecast to 2021

“Myasthenia Gravis Drugs Market”
The analysts forecast the global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.

 

 

Global Myasthenia Gravis Drugs Market

WiseGuyRerports.com Presents “Global Myasthenia Gravis Drugs Market 2017-2021” New Document to its Studies Database. The Report Contain 73 Pages With Detailed Analysis.

Description

Currently, the myasthenia gravis drugs market stands at a small size due to limited availability of approved therapies for the complete remission of the disease. However, the anticipated approval of novel drugs such as monoclonal antibodies should help market witness strong growth during the forecast period. For instance, Alexion Pharmaceuticals is currently developing a monoclonal antibody, Soliris, for the treatment of myasthenia gravis. Once launched around end 2017 or beginning of 2018, this drug is expected to be the blockbuster drug for the market.

The analysts forecast the global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the period 2017-2021.

Covered in this report 
The report covers the present scenario and the growth prospects of the global myasthenia gravis drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of myasthenia gravis drugs.

 

Get sample Report @ https://www.wiseguyreports.com/sample-request/895588-global-myasthenia-gravis-drugs-market-2017-2021

 

The market is divided into the following segments based on geography: 
• Americas 
• APAC 
• EMEA

The Global Myasthenia Gravis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors 
• Flamel Technologies 
• F. Hoffmann-La Roche 
• Grifols 
• Pfizer 
• Shire 
• Valeant Pharmaceuticals

Other prominent vendors 
• Alexion Pharmaceuticals 
• Catalyst Pharmaceuticals 
• CSL 
• Curavac 
• Cytokinetics 
• Galencia 
• GlaxoSmithKline 
• Lupin Pharmaceuticals 
• Mitsubishi Tanabe Pharma 
• Novartis

Market driver 
• Approval of novel monoclonal antibodies 
• For a full, detailed list, view our report

Market challenge 
• Limited availability of approved drugs 
• For a full, detailed list, view our report

Market trend 
• Emergence of new entrants 
• For a full, detailed list, view our report

Key questions answered in this report 
• What will the market size be in 2021 and what will the growth rate be? 
• What are the key market trends? 
• What is driving this market? 
• What are the challenges to market growth? 
• Who are the key vendors in this market space? 
• What are the market opportunities and threats faced by the key vendors? 
• What are the strengths and weaknesses of the key vendors?

 

Complete Report Details @ https://www.wiseguyreports.com/reports/895588-global-myasthenia-gravis-drugs-market-2017-2021

 

Table of Contents -Major Key Points

PART 01: Executive summary 

PART 02: Scope of the report 
• Market overview 
• Top-vendor offerings 

PART 03: Market research methodology 
• Research methodology 
• Economic indicators 

PART 04: Introduction 
• Key market highlights 
• Highlights 

PART 05: Pipeline analysis 

PART 06: Market landscape 
• Global myasthenia gravis drugs market 
• Five forces analysis 

PART 07: Market segmentation by therapy area 
• Anticholinesterases 
• Immunosuppressants 
• IVIg 

PART 08: Geographical segmentation 
• Myasthenia gravis drugs market in Americas 
• Myasthenia gravis drugs market in EMEA 
• Myasthenia gravis drugs market in APAC 

PART 09: Market drivers 
• Approval of novel monoclonal antibodies 
• High unmet medical need 
• Growing research activities for the better understanding and diagnosis of myasthenia gravis 

PART 10: Impact of drivers 

PART 11: Market challenges 
• Presence of substitutes 
• Limited availability of approved drugs 
• Lack of long-term commitment 

PART 12: Impact of drivers and challenges 

PART 13: Market trends 
• Emergence of new entrants 
• Growing strategic acquisitions 
• Potential treatment options 

PART 14: Vendor landscape 
• Competitive scenario 

PART 15: Key vendor analysis 
• Flamel Technologies 
• F. Hoffmann-La Roche 
• Grifols 
• Pfizer 
• Shire 
• Valeant Pharmaceuticals 
• Other prominent vendors 

………..CONTINUED

 

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com